Nevirapine Accord

Nevirapine, the active ingredient in Nevirapine Accord, is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral use. It is employed in combination regimens to treat HIV-1 infection in adults and adolescents, helping to suppress viral replication and improve immune function.

GNH USA supplies Nevirapine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is an antiretroviral medication used in the management of HIV‑1 infection as part of combination therapy.

- HIV‑1 infection (treatment): Reduces viral load when used with other antiretroviral agents. - Treatment‑experienced HIV‑1 patients: Provides an alternative option for those with resistance to other drugs. - Pediatric HIV‑1 infection (≥2 kg): Used under specialist supervision as part of a regimen for children.

Nevirapine may cause a range of adverse reactions, from mild to severe. Monitoring for side effects is essential during therapy.

Common Side Effects: - Rash: Often mild, may appear on trunk or limbs. - Headache: Transient, usually resolves without intervention. - Nausea: May be accompanied by mild abdominal discomfort. - Fatigue: Generalized tiredness reported by some patients. - Diarrhea: Loose stools occurring early in treatment. - Elevated liver enzymes: Detected in routine blood tests.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: Severe skin reaction requiring immediate medical attention. - Hepatotoxicity: Significant liver injury, presenting with jaundice or elevated bilirubin. - Severe hypersensitivity: Includes fever, eosinophilia, and organ involvement. - Hematologic abnormalities: Such as anemia or neutropenia. - Immune reconstitution syndrome: Worsening of opportunistic infections after immune recovery.

Before initiating Nevirapine, clinicians should assess patient history and monitor for potential risks.

- Liver function: Evaluate baseline hepatic enzymes and monitor regularly. - Skin reactions: Inspect for rash; discontinue if severe or progressing. - Pregnancy: Use only if benefits outweigh risks; consult specialist. - Drug resistance: Perform resistance testing when possible. - Concomitant medications: Review for interactions that affect metabolism. - Store at ambient temperature: Keep below 25 °C, in original packaging, protected from moisture and direct sunlight.

Nevirapine interacts with several drug classes, influencing efficacy and safety.

Major Interactions (Avoid): - Rifampicin: Reduces nevirapine plasma levels, compromising antiviral effect. - Carbamazepine: Induces metabolism, leading to subtherapeutic concentrations. - St. John's wort: Potent CYP3A4 inducer, markedly decreasing nevirapine exposure.

Moderate Interactions (Monitor Closely): - Protease inhibitors (e.g., ritonavir): May increase nevirapine levels, requiring dose adjustment. - Hormonal contraceptives: Potential reduction in contraceptive efficacy. - Warfarin: May alter anticoagulant effect; monitor INR closely.